Crinetics Pharmaceuticals, Inc. announced on July 13, 2025, new long-term data from its clinical development program for once-daily, oral investigational PALSONIFY (paltusotine) in acromegaly, presented at ENDO 2025.
Open-label extension (OLE) data from both the pivotal PATHFNDR-1 and PATHFNDR-2 trials demonstrated that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term use. In the PATHFNDR-1 OLE, 91% of participants entered, with data through Week 96 showing sustained disease control.
Patients switching from injected somatostatin receptor ligands to PALSONIFY in the PATHFNDR-1 study experienced a significant reduction in day-to-day symptom exacerbations, dropping from over 30% of days to just 6.2% during stable PALSONIFY dosing (p < 0.0001). This further supports PALSONIFY's potential to deliver durable IGF-1 control and sustained improvements in patient symptom burden.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.